A Study of Distal Jejunal-release Dextrose in Obese Participants

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

November 11, 2024

Study Completion Date

November 11, 2024

Conditions
Obese
Interventions
DRUG

APHD-012

Distal jejunal-release dextrose beads (Aphaia technology, AT)

DRUG

APHD-012P

Distal jejunal-release placebo beads

Trial Locations (9)

16816

Universitätsklinikum Ruppin-Brandenburg, Neuruppin

23538

Universitätsklinikum Schleswig-Holstein, Lübeck

0112

"LTD Israeli-Georgian Medical Research Clinic Healthycore", Tbilisi

0159

"LTD Acad. G. Chapidze Emergency Cardiology Center", Tbilisi

"LTD Diacor", Tbilisi

"LTD National Institute of Endocrinology", Tbilisi

0186

"LTD Tbilisi Heart Center", Tbilisi

00917-3104

GCM Medilcal Group, San Juan

Unknown

FDI Clinical Research, San Juan

Sponsors
All Listed Sponsors
lead

Aphaia Pharma US LLC

INDUSTRY

NCT05385978 - A Study of Distal Jejunal-release Dextrose in Obese Participants | Biotech Hunter | Biotech Hunter